在随机III期试验(IXORA-P)中,依奇珠单抗每2周连续给药52周治疗中重度斑块状银屑病的疗效与安全性
这项III期多中心双盲平行组试验将中重度斑块状银屑病患者按2:1:1随机分为依奇珠单抗每2周连续给药组(n=611)、每4周连续给药组(n=310)和按方案调整剂量组(Q4W/Q2W,n=306),每组均以160 mg起始。第52周时,每2周组与每4周组的PASI 75应答率分别为85.9%和79.0%(P=0.006),静态患者总体评估0/1应答率分别为78.6%和70.6%(P=0.005);治疗中出现的不良事件和严重不良事件在各剂量组间相当。
要点
- 第52周PASI 75应答率:每2周组85.9% vs 每4周组79.0%(P=0.006)。
- 第52周静态患者总体评估0/1应答率:每2周组78.6% vs 每4周组70.6%(P=0.005)。
- 治疗中出现的不良事件和严重不良事件在各剂量组间相当。
核心结论
- 依奇珠单抗每2周给药在第52周的疗效高于每4周给药,且安全性事件未增加。
研究设计与样本
- III期、多中心、双盲、平行组试验,中重度斑块状银屑病患者按2:1:1随机分为每2周连续给药组(n=611)、每4周连续给药组(n=310)和按方案调整剂量组(Q4W/Q2W,n=306),每组均以160 mg起始。
主要发现
- 第52周PASI 75应答率:每2周组85.9% vs 每4周组79.0%(P=0.006)。
- 第52周静态患者总体评估0/1应答率:每2周组78.6% vs 每4周组70.6%(P=0.005)。
- 治疗中出现的不良事件和严重不良事件在各剂量组间相当。
关键数值与推荐
- 共同主要终点在第52周达到:PASI 75应答率每2周组85.9% vs 每4周组79.0%(P=0.006)。
- 静态患者总体评估0/1应答率每2周组78.6% vs 每4周组70.6%(P=0.005)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ixekizumab is an interleukin-17A antagonist approved for treatment of moderate-to-severe plaque psoriasis with a recommended 160-mg starting dose, then 80 mg every 2 weeks (Q2W) to week 12, and every 4 weeks (Q4W) thereafter. OBJECTIVE: To evaluate continuous Q2W dosing over 52 weeks. METHODS: In this phase III, multicentre, double-blinded, parallel-group trial, three ixekizumab dosing regimens were assessed for efficacy and safety at week 52 in patients with moderate-to-severe plaque psoriasis randomized at a 2 : 1 : 1 ratio to continuous Q2W (n = 611), continuous Q4W (n = 310) or dose adjustment per protocol (Q4W/Q2W, n = 306), each with a 160-mg starting dose. Dose adjustment was determined by predefined criteria to which investigators were blinded; 72 (23?5%) patients in the Q4W/Q2W group adjusted dose. Efficacy outcomes were evaluated using logistic regression. RESULTS: Co-primary end points were met at week 52: Psoriasis Area and Severity Index 75 responses for Q2W and Q4W dose groups were 85·9% and 79·0%, respectively (P = 0·006), and static patient global assessment 0/1 responses for Q2W and Q4W dose groups were 78·6% and 70·6%, respectively (P = 0·005). Treatment-emergent and serious adverse events were comparable across dose groups. CONCLUSIONS: Ixekizumab Q2W had higher efficacy at week 52 than ixekizumab Q4W, with no increase in safety events.
引用
- Langley RG, Papp K, Gooderham M, et al. Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P). Br J Dermatol. 2018. PMID: 29405255. doi:10.1111/bjd.16426
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。